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Abstract 
 
 The aim of this dissertation is to understand the applications of nanotechnology 
in the delivery of drugs in pancreatic cancer therapy. It was necessary to realize the 
pathogenesis of pancreatic cancer, as well as the reasons why conventional therapies 
currently used do not provide a significant increase in patient survival. 
 Pancreatic cancer is one of the most lethal cancers in the world, mainly because 
of the inability to diagnose it in a timely manner and the lack of effectiveness of existing 
treatments. In this way, the development of new innovative therapies has become 
fundamental. 
 In the last decade, nanomedicine has gained increasing prominence as a new 
approach for the delivery of drugs, since it allows the transport of the drugs to the specific 
region and in established concentrations, reducing in this way the systemic toxicity. 
Several studies are related to different types of nanoparticles (lipid, polymer and metal), 
highlighting the advantages and disadvantages of each of them, as well as some drugs 
already marketed using nanotechnology. 
 A model administration system was developed for the delivery of Parvifloron 
D. The characteristics selected were related to the properties of the drug to be 
encapsulated, with diameters of 200nm, negative zeta potential, IdP of 0.200 and 
connection efficiency of 97%. The toxicity of the formulation was also evaluated, and it 
was concluded that the lower concentration nanoparticles (30 μM) provided a growth 
inhibition of 3.2% Saccharomyces cerevisiae, and at the highest concentration (53 μM) 
of 15.6%. 
 These results lead us to believe that through further studies it may be possible 
to use this optimized formulation as a suitable and promising carrier of Parvifloron D, 
and thus contribute to a therapeutic alternative for pancreatic cancer. 
 
Keywords: Pancreatic cancer; Nanomedicine; Nanoparticle; Drug delivery; Parvifloron 
D. 
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Resumo 
 
 O objetivo desta dissertação prende-se com a compreensão das aplicações da 
nanotecnologia na vectorização de fármacos na terapia do cancro do pâncreas. Para tal 
foi necessário perceber a patogénese do cancro do pâncreas, bem como os motivos pelos 
quais as terapias convencionais atualmente utilizadas não proporcionam um aumento 
significativo da sobrevivência dos doentes.   
O cancro do pâncreas representa um dos cancros mais letais no mundo, devido 
sobretudo à incapacidade de diagnosticá-lo em tempo hábil e à falta de eficácia dos 
tratamentos existentes. Desta forma, o desenvolvimento de novas terapias inovadoras 
tornou-se fundamental.  
Na última década, a nanomedicina tem ganho cada vez mais destaque como uma 
nova abordagem para a vectorização de fármacos, uma vez que possibilita o transporte 
dos fármacos até à região específica e em concentrações estabelecidas, reduzindo desta 
forma a toxicidade sistémica. São abordados diversos estudos relacionados com 
diferentes tipos de nanopartículas (lipídicas, poliméricas e metálicas), salientando as 
vantagens e as desvantagens de cada um deles, bem como alguns fármacos já 
comercializados com recurso à nanotecnologia.  
Foi desenvolvido um sistema de administração modelo para vectorização de 
Parviflorona D. As características selecionadas foram de encontro às propriedades do 
fármaco a encapsular, sendo que obtivemos diâmetros de 200nm, potencial zeta negativo, 
IdP de 0,200 e eficiência de ligação de 97%. A toxicidade da formulação também foi 
avaliada, e concluiu-se que as nanopartículas de menor concentração (30 μM) 
proporcionaram uma inibição de crescimento de 3,2% de Saccharomyces cerevisiae, e na 
maior concentração (53 μM) de 15,6%.  
Estes resultados levam-nos a acreditar que mediante mais estudos possa ser 
possível utilizar esta formulação otimizada como sistema de veiculação adequado e 
promissor da Parviflorona D, e desta forma contribuir para uma alternativa terapêutica 
para o cancro do pâncreas.  
 
Palavras Chave: Cancro pancreático; Nanomedicina; Nanopartícula; Veiculação de 
fármacos; Parviflorona D.
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Introduction 
 
 Pancreatic cancer is one of the leading causes of cancer death worldwide and is 
more common in men and has a 5-year survival rate of less than 5%. This is due to the 
lethal nature of this type of cancer, since it can rapidly spread to the lymphatic system 
and distant organs, being mostly asymptomatic up to stage IV. The presence of 
imperceptible metastases when the diagnosis occurs, together with the inefficiency of the 
treatments that currently exist due to the intrinsic resistance of the tumor cells to the 
chemotherapeutic agents, contribute to the high mortality rate. 1,2 
 Chemotherapy is currently the most common treatment option, although it 
allows for minimal survival. Currently, gemcitabine is the first-line chemotherapy agent, 
prolonging overall survival in only 6 to 12 weeks. However, its benefits are compromised 
by its low half-life and low relative concentration around the tumor tissue. In this way, 
new and effective therapies are urgently needed. 3,4,5,6 
Nanotechnology is based on a multidisciplinary science that addresses the 
development and preparation of systems with a nanometer scale. This science comprises 
the use of particles with a size between 1-1000nm, which depending on their size, can 
alter properties such as stability, reactivity, and the ability to interact with other molecules 
and systems. 7,8 
In this way, this type of technology gives us the possibility to investigate new 
methods that can be applied positively in the various scientific areas. The application of 
nanotechnology in the field of medicine emerges as a new field of interdisciplinary 
research, which in the last decade has been increasingly expressed, since it has added 
value both in the diagnosis and in the treatment of various pathologies. 9,10 
 Several studies have been carried out involving nanotechnology and pancreatic 
cancer, already existing several marketed products based on nanotechnology as oncology 
therapy. Different types of nanoparticles, such as lipid, polymeric and metallic, have been 
used to understand the best formulation to obtain more efficacy in pancreatic tumor tissue.  
 One of the main challenges is the toxicity associated with this type of 
formulations, as well as their stability. However, the studies that exist refer to the 
encapsulation of existing chemotherapeutic agents, such as gemcitabine, the first-line 
agent in the treatment of pancreatic cancer. 
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 Currently, about 60% of the antitumor medications used clinically come from 
natural products. There is a class called terpenoids, which have medicinal properties, 
especially anticancer, since most of them induce the death of tumor cells, targeting the 
apoptotic pathways. 11,12 
 In this dissertation, the development of a formulation of serum albumin 
nanoparticles (the most abundant protein in blood plasma, biocompatible, biodegradable 
and non-toxic), with specific characteristics to vector the main compound of Plectranthus 
ecklonii called Parvifloron D (PvD). 13,14 
 This compound inhibits the proliferation of cancer by apoptosis in some cancer 
cell lines, such as human myeloid leukemia, human melanoma, and breast cancer, thus 
becoming a target of interest for pancreatic cancer. PvD demonstrates lack of specificity 
and some cytotoxic effects in non-cancer cell lines, so developing a formulation that can 
effectively encapsulate it may indicate a solution to deliver this drug into pancreatic 
cancer tissue without undesirable effects. 15 
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1.1 Anatomophysiology of pancreas 
 
 The pancreas is an acinar tubular gland, located in the retroperitoneal space, 
between the large curve of the stomach and the duodenum, arranged transversely in the 
upper wall of the abdomen. It has an elongated and flat structure, which measures about 
15 centimeters in length and weighs between 85g and 100g.16  
 This organ consists of the head, which is in contact with the duodenal loop and 
separated from the body of the pancreas, through an isthmus, a restricted zone, bounded 
by two cracks, by the body, slightly oblique part from below to and from the right to the 
left, disposed frontally to the aorta and the inferior vena cava, and by the tail, which is in 
contact with the spleen and is lined by the parietal peritoneum, as shown in Figure 1.17  
 
 
 
 
 
 
 
 
 
 
 
 
  
 The pancreas is a mixed gland, with endocrine and exocrine functions. The 
exocrine pancreas plays a key role in the digestive process. The stomach secretes food 
partially digested into the duodenum in the form of chyme, consisting of food bolus, 
hydrochloric acid, gastric juice, and digestive enzymes (pepsins). It reaches the 
duodenum through the Wirsung duct, which leads to the Vater ampule, and the Santorini 
duct, which flows 3 to 4 cm above. Pancreatic acini (Figure 2) release pancreatic juice to 
complete the process of chyme digestion in the duodenum. 18  
 
Duodenal papila 
Duodenal of small 
intestine 
Head of pancreas 
Bile duct 
Pancreatic ducts 
Inferior 
vena cava 
Abdominal 
aorta 
Body of pancreas 
Spleen 
Tail of 
pancreas 
Figure 1. Structure and connections of the pancreas. 17  
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 Pancreatic juice is composed of water, salts, bicarbonate, and numerous 
digestive enzymes, and through this constitution, namely the bicarbonate ions, it is 
possible to neutralize the acid present in the chyme to protect the intestinal wall and to 
create the proper environment for the good performance of pancreatic enzymes. 18  
The enzymes present in the pancreatic juice are: 
• Proteolytic enzymes, whose function is the digestion of proteins. They are divided 
into exopeptidases (such as carboxypeptidase), which act on the chemical bonds 
between amino acids, from a terminal end of the protein, and into endopeptidases 
(such as chymotrypsin and trypsin), which degrade proteins by cleaving chemical 
bonds between the amino acids of the protein molecule.19 
• Glycolytic enzymes, or amylases, contribute to the digestion of carbohydrates and 
sugars. These enzymes hydrolyze the α-bonds throughout the starch chain, that is, 
they transform all the carbohydrates that were not attacked by ptyalin and reach the 
duodenum in a mixture and elemental sugars (glucose and maltose), capable of 
crossing easily the intestinal mucosa, passing into the bloodstream; 20 
• Lipolytic enzymes, or lipases, whose function is to digest lipids or fats. The lipases 
hydrolyze the fats, transforming them into glycerol-free fatty acids, easily assimilated 
by the cells. In addition to this function, they also break down neutral fats or 
triglycerides into fatty acids and glycerin.21 
• Nucleases, enzymes that promote the digestion of nucleic acids. Ribonuclease has the 
function of cleaving RNA molecules in the sugar ribose and in the nitrogenous bases 
adenine, cytosine, guanine, and uracil, while the deoxyribonuclease digests the DNA 
molecules in the sugar deoxyribose and in the nitrogen bases adenine, cytosine, 
guanine, and thymine. They are enzymes of two types (α and β) that catalyze the 
hydrolysis of the phosphodiesteric bonds.22  
Figure 2. Histological image of a pancreatic acini. 18 
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 The endocrine pancreas controls the blood glucose homeostasis previously 
discussed. Glucose levels in the bloodstream should be controlled so that there is a 
constant supply of glucose to the cells. High levels of glucose can cause damage to the 
kidney as well as to other organs. The pancreas produces two antagonistic hormones that 
control this homeostasis, being glucagon and insulin. 23  
 Glucagon is produced by α-cells and accumulates within the secretory granules 
from which it is released by exocytosis at the time of hypoglycemia. In the liver, this is 
recognized by hepatocytes and by the presence of a receptor that, when it binds to this 
hormone, causes a chain of phosphorylation reactions that activate the enzymes of 
glycogen lysis and glucose synthesis, causing a greater release of glucose into the 
bloodstream. It also stimulates adipose tissue to metabolize triglycerides into glucose. It 
plays an important role in facilitating amino acid uptake, active phagocytosis process, 
among others. 24 
 Unlike glucagon, insulin has the function of lowering blood glucose after a meal 
by stimulating the absorption of glucose by the liver, muscle, and adipose tissues. Insulin 
is produced in β-cells, and when there is a peak of glucose in the blood, insulin is released 
to systemic circulation, increasing the glucose uptake by the cells by binding to the 
membrane receptor tyrosine kinase. This receptor activates the exocytosis of GLUT4 
transporter molecules specific glucose tolerance. When the extracellular concentration of 
glucose is reduced, GLUT2 is transported back into the cell by endocytosis and stored in 
vesicles for later use.25  
 Insulin also stimulates glycolysis, that is, increases the intracellular use of 
glucose and facilitates its transformation into glycogen (in the liver or muscles) or into 
triglycerides (adipose tissue). In addition, insulin has the function of stimulating lipid 
metabolism, favoring the passage of free fatty acids, from plasma to adipocytes, which 
convert them into triglycerides, reducing the mobilization of fats and inhibiting their 
oxidative dissolution, as well as acts on the metabolism of proteins, facilitating the 
transport of amino acids to the cells. 16, 25, 18 
 Insulin secretion is mediated by glycemia through a negative feedback 
mechanism. Β cells are very sensitive to blood glucose levels, so that by massively 
flowing through the membrane, it causes a series of biochemical reactions that end with 
depolarization of the cell. By activating a system of microtubules and microfilaments, the 
flow of Ca 2+ ions promote the excretion of this hormone. 27  
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 The regulation of pancreatic function is performed by the autonomic nervous 
system (ANS) and the endocrine system. The ANS divides into sympathetic and 
parasympathetic. Sympathetic innervation becomes active when situations of stress, 
emergencies or exercise occur. Sympathetic neurons stimulate the alpha cells of the 
pancreas to secrete glucagon into the bloodstream. In turn, glucagon stimulates the liver 
to initiate cleavage of glycogen into small molecule glucose molecules. 28  
 Glucose is then released into the bloodstream to achieve especially the cardiac 
and skeletal muscle. At the beta cell level, sympathetic innervation also acts to reduce the 
secretion of pancreatic juice and insulin, which would counteract the intended effect. The 
parasympathetic innervation becomes active during the rest and digestion, acting by 
stimulating the release of insulin and pancreatic juice. 28 
 The endocrine system uses two hormones to regulate digestive function, such 
as secretin and cholecystokinin (CCK). Secretin is produced by the cells of the lining of 
the duodenum, in response to the arrival of the chyme. This hormone stimulates the 
secretion of bicarbonate and water by the pancreas and inhibits the formation of gastrin 
by the stomach. CCK is also produced by the same cells that produce secretin in response 
to the presence of proteins and fats in the chyme. This hormone travels through the 
bloodstream and binds to pancreatic acini to stimulate these cells to produce and secrete 
pancreatic juice, rich in digestive enzymes, that break down the protein molecules into 
peptones and reduce the lipid molecules in microdroplets soluble and assimilable by 
intestinal cells. 29,30 
 
1.2 Diseases of the pancreas: non-oncologic 
 
 There are several pancreatic pathologies, including acute or chronic pancreatitis 
and hereditary pancreatitis. The main problem of these pathologies is their diagnosis, due 
to the inaccessibility of the organ itself. Initially, the medical team begins by performing 
a physical examination using palpation but is often inconclusive since the pancreas lies 
deep in the abdomen near the spine. 31 
 Subsequently they performed hematological examinations to verify if there are 
signs of inflammation that lead to a diagnosis, but that can lead to a false conclusion. 
Radiographic examinations are the best way to evaluate the structure of the pancreas, 
namely computed tomography (CT), endoscopic ultrasound, and magnetic resonance 
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(MR). There are also tests to evaluate the pancreatic ducts such as endoscopic retrograde 
cholangiopancreatography and magnetic resonance cholangiopancreatography. There are 
cases in which it is only through surgical exploration that one can confirm the diagnosis, 
but this method is the last approach due to its invasive character. 31 
 
 1.2.1 Acute pancreatitis 
 
 This pathology is defined as an inflammation of the pancreas which is usually 
associated with high abdominal pain, which can be painful and its durability long. In 
addition to these symptoms, nausea, vomiting, diarrhea, swelling and fever may still 
occur. In the United States, this pathology is caused mostly by gallstones. Other causes 
include chronic alcohol consumption, heredity, trauma, drugs, infections, electrolyte 
changes, high lipid levels, hormonal changes, or unknown factors. Most patients with this 
pathology recover completely after pharmacological treatment. 32 
 
1.2.2 Chronic pancreatitis 
 
Chronic pancreatitis is associated with the destruction of the organ itself in the 
long term. It is a pathology that affects mostly men between 30 and 40 years of age. 
Initially, it can be confused with the acute one since the symptoms are similar, with high 
abdominal pain and diarrhea being the most prevalent. As the disease progresses, patients 
may present themselves with malnutrition and considerable weight loss. If the pancreas 
is destroyed in the late stages of the disease, patients may develop diabetes mellitus due 
to lack of insulin production by the organ itself. The most common cause of chronic 
pancreatitis in the United States is alcoholism, and there are other causes, such as cystic 
fibrosis for example.33 
The treatment of this pathology depends mainly on the symptoms that the patient 
presents. In most cases, the therapy is focused on pain control and nutritional support. 
Pancreatic enzyme oral supplements are used to aid the digestion process. For patients 
who develop diabetes mellitus, a supply of insulin is needed to control blood glucose 
levels. For alcohol consumers, abstinence from alcohol is essential. 31,33 
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2.1 Types of cancer 
 
 Pancreatic cancer is one of the leading causes of death worldwide and is 
considered the 7th leading cause of cancer-related death. In 80% of cases, this develops 
in the exocrine part. About 75% of cancers in the exocrine pancreas are located inside the 
head of the pancreas, 15 to 20% in the body and only 5 to 10% in the tail of this organ. 
34,35  
 For pancreatic cancer located in the exocrine part ductal adenocarcinoma is the 
most diagnosed, accounting for about 95% of cases. This lesion produces an intense 
stromal reaction postulated that has the function of resisting chemotherapy. 36,37 
 This type of cancer usually begins in the pancreatic ducts, being less frequent 
to develop from the cells that produce the pancreatic enzymes, in which acquires the name 
acinar cellular carcinoma. The latter is morphologically prominent by significant acinar 
cell differentiation, by cytoplasmic granules and prominent single-nucleus. 38 
 Figure 3 demonstrates the evolution of normal pancreatic duct epithelium to 
pancreatic adenocarcinoma through early events (shortened telomerase, KRAS mutation, 
p16 loss) and at a more advanced stage (p53 loss, SMAD4 / DPC gene loss). This scheme 
is ilustred that the cancer of the pancreas is a result of hereditary line germination somatic 
mutations are acquired in cancer-related genes (oncogenes, tumor suppressor genes, cell 
cycle genes, genes for apoptosis and genome maintenance). Also, cell turnover, 
telomerase shortening and genomic instability may be responsible for the progression of 
pancreatic epithelial cells in tumor cells. 39 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Progression to pancreatic cancer. 39 
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Pancreatic intraepithelial neoplasm (PanIN) is usually located in the small 
pancreatic duct and is divided into 3 groups by epithelial atypia, PanIN-1 (minimum 
atypia), which also has 2 subgroups, i.e. PanIN-1A (flat type) and PanIN-1B (papillary 
type), PanIN-2 and PanIN-3 (limited atypia). This type of neoplasm is associated with 
invasive carcinoma and chronic pancreatitis, and HER-2/neu expression is 82% in PanIN 
1A, 86% in PanIN 1B and 92% in PanIN-2. 40 
In addition to the above, there are also cystic neoplasms of the pancreas. 
Pancreatic cysts are common, some of which are curable precursors of a possible ductal 
adenocarcinoma. Within these neoplasms we firstly have the intraductal papillary 
mucinators, located in the exocrine pancreas. This type of lesion is defined by non-
invasive productions of papillary mucin and arise in the larger pancreatic ducts. Because 
they are large they are easily detected in imaging tests and detected in time can prevent 
the appearance of a more invasive cancer. 36,37,41,42 
 Secondly, mucosal cystic neoplasms (MCNs), which are related to well-defined 
tumors with mucin-producing cysts and septation with distinctive ovarian-like stroma 
without communication with the ductal system. It is usually a single lesion consisting of 
a thick fibrous wall. This type of neoplasm can be invasive and non-invasive. Noninvasive 
MCNs are subdivided into MCNs with low grade dysplasia, moderate dysplasia, or high-
grade dysplasia. 36,40,43  
 Third, we have the serous cystadenoma (SCAs, in which the cysts are mostly 
benign and slow-growing, coated by non-mucinous epithelium. Finally, solid 
pseudopapillary neoplasia, very rare. This type of lesion usually has a favorable 
prognosis, although it is mostly malignant. 37,43,44,45,46 
 Tumors of the endocrine or neuroendocrine pancreas (NETs) are uncommon, 
accounting for less than 5% of all pancreatic cancers. These tumors may be benign or 
malignant, and at the microscopic level they may be quite similar, not often being 
noticeable. For the most part, they are only diagnosed as malignant when they spread 
outside the pancreas. There are several types of NETs: 
• Functional NETs: about 50% of the neuroendocrine tumors produce hormones 
that are released into the bloodstream and thus trigger some symptoms. Each 
type of tumor is called a hormone that secretes. 
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o Gastrinomas are derived from gastrin-producing cells. About 50% of 
these malignant ones; 
o Insulinomas are derived from insulin-secreting cells. Most are benign; 
o Glucagonomas are derived from cells that produce glucagon. Most are 
very severe; 
o In addition to these there are still somatostatinomas (somatostatin), 
VIPomas (vasoactive intestinal peptideomas) and the PPomas 
(pancreatic polypeptideomas); 
• Nonfunctional NETs: This type of tumor does not produce enough hormones 
to cause symptoms, so they are more likely to develop cancer because they are 
asymptomatic. 
• Carcinoid tumors: rarely has onset in the pancreas, being more common in 
other parts of the digestive system. They usually produce serotonin (5-HT) or 
its precursor, 5-HTP. 
Finally, we have pancreatoblastomas, which are rare solid cell neoplasms and where 
their location is still not well described. They consist of multiple cellular compounds, 
such as the acinar component. 47,48,49 
 
2.2 Cancer stages 
 
The American Joint Committee on Cancer has created a tumor-nodule-metastasis 
classification system to evaluate the stage and type of pancreatic cancer. The evaluation 
items are: tumor size and its relation to the vitality of the blood vessels, used to 
characterize the tumor from TX to T4; the extension of the lymph node surrounding 
region determines nodal classification ranging from NX to N1; the presence and / or 
absence of identifiable metastases in distant organs designates the metastatic category as 
M0 or M1, respectively (Tables 1 and 2).50 
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Table 1. International classification of malignant tumors for pancreatic cancer. 50 
 
 
Table 2. International classification of malignant tumors: stages of pancreatic cancer. 50 
Primary tumor (T) Regional lymph nodes (N) Distant metastasis (M) 
TX Primary tumor cannot be assessed NX 
Regional lymph nodes 
cannot be assessed 
M0 
No distant 
metastasis 
T0 No evidence of primary tumor N0 
No regional lymph node 
metastasis 
M1 Distant metastasis 
Tis Carcinoma in situ N1 
Regional lymph node 
metastasis 
T1 
Tumor limited to the pancreas, 2 cm or 
less in greatest dimension 
T2 
Tumor limited to the pancreas, more 
than 2 cm in greatest dimension 
T3 
Tumor extends beyond the pancreas but 
without involvement of the celiac axis or 
the superior mesenteric artery 
T4 
Tumor involves the celiac axis or the 
superior mesenteric artery; unresectable 
primary tumor 
Stage Primary tumor  Regional lymph nodes  Distant metastasis  
0 Carcinoma in situ 
No regional lymph node 
metastasis 
No distant metastasis 
IA 
Tumor limited to the pancreas, 2 cm or 
less in greatest dimension 
No regional lymph node 
metastasis 
No distant metastasis 
IB 
Tumor limited to the pancreas, more 
than 2 cm in greatest dimension 
No regional lymph node 
metastasis 
No distant metastasis 
IIA 
Tumor extends beyond the pancreas 
but without involvement of the celiac 
axis or the superior mesenteric artery 
No regional lymph node 
metastasis 
No distant metastasis 
IIB 
Tumor limited to the pancreas; Tumor 
extends beyond the pancreas but 
without involvement of the celiac axis 
or the superior mesenteric artery 
Regional lymph node 
metastasis 
No distant metastasis 
III 
Tumor involves the celiac axis or the 
superior mesenteric artery; 
unresectable primary tumor 
No regional or regional 
lymph node metastasis   
No distant metastasis 
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2.3 Pathogenesis of pancreas cancer 
 
 Advances in the knowledge of the pathogenesis of pancreatic cancer have been 
increasing in the last decade, which is a plus for developing more effective diagnostic 
methods and therapies. Multiple subsets of genes have been discovered that undergo 
activation or deactivation during the progression of this type of cancer. Activation of 
oncogenes (point mutation, amplification) and inactivation of tumor suppressor genes are 
responsible for the process of initiating the development of pancreatic cancer. Although 
all the genetic changes described above are complex, the recognition that they represent 
a basic set of processes that are essential for understanding pancreatic cancer. 36,51,52 
 Somatic mutations, genetic alternations, and the germ line are responsible for 
pancreatic cancer. There are sixteen identified mutated oncogenes, including KRAS, 
TP53, CDKNA2A, SMAD4, MLL3, TGFBR2, ARID1A, SF3B1, EPC1, ARID2, ATM, 
ZIM2, MAP2K4, NALCN, SLC16A4, MAGEA6. 37,40,39 
 The KRAS oncogene undergoing a mutation, most often at codon 12, but may 
also occur at codon 61 and 13, results in 90% of cancerous pancreatic cells and 20% of 
these are whole body cells. This oncogene negatively affects cell life and functions, such 
as cell differentiation and proliferation. 41 
 A mutation in KRAS induces the formation of ductal precancerous formations 
and causes hyperplastic multifocal focus in the pancreatic duct. It is also responsible for 
the activation of many signaling pathways, such as the activated P13K-AKT pathway, 
which affects cell life and cell circulation; the MEK and ERK1 / 2 pathway, which upon 
activation affects angiogenesis, cell proliferation, cellular apoptosis, carcinogenic cell 
migration and cell cycle regulation; the notch pathway, which activated, affects cell 
proliferation, cell differentiation and cellular apoptosis, and the Hedgehog pathway, 
IV 
Tumor limited to the pancreas; Tumor 
extends beyond the pancreas but 
without involvement of the celiac axis 
or the superior mesenteric artery; 
Tumor involves the celiac axis or the 
superior mesenteric artery; 
unresectable primary tumor 
No regional or regional 
lymph node metastasis   
Distant metastasis 
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which causes metastases. Activation of STAT3 has also been identified in patients with 
pancreatic cancer, and the inhibitors of this oncogene are already used in the treatment of 
this oncological pathology. 53 
 MiRNAs are involved in the development of pancreatic tumors and perform 
oncogenic functions. Among the 1,000 that exist, pancreatic cancer functions are miRNA-
196a, miRNA-190, miRNA-186, miRNA-200b, miRNA-15b, miRNA-95, miRNA-21, 
miRNA-155, miRNA -221 and miRNA-222. 54 
 Tumor suppressor genes have the function of protecting the cell cycle or 
promoting apoptosis of tumor cells. A mutation of p53 (protein with functions in the 
maintenance G2-M, regulating the G1-S control point of the phases of the cell cycle, 
inducing apoptosis, regulating the senescence, repairing the DNA, and altering the 
cellular metabolism), that is, the inactivation of this protein by missense conjugated 
mutations with loss of the remaining allele, is common in about 75% of cases ductal 
adenocarcinoma. The functional loss of this protein also allows survival and cell division 
in the presence of DNA damage, which promote the accumulation of other anomalies. 
36,55 
 Mutations and deletions in DPC4 (locus 4), LKB1 (kinase B1, present in the 
liver) and INK4a are found in 95% of pancreatic cancer cases, and deletion MKK4 
(mitogen-activated protein kinase 4) is observed in patients with cancer in the pancreas, 
DPC4 triggers metastases even though it is not present in pancreatic cancer, and the 
mutation of the LKB1 gene causes Peutz-Jeghers syndrome, associated with pancreatic 
cancer. 39 
 
2.4 Risk factors, signs and symptoms 
 
 Risk factors are related to any characteristic, action or habit that contributes to 
the development of a cancerous process. Some of these factors, such as smoking habits, 
can be changed. However, there are others, such as age or family history, that are 
unalterable. Presenting one or several risk factors characteristic of a pathology does not 
mean that the disease develops. Smoking is known as the major risk factor for the 
development of pancreatic cancer, although the exact mechanism of cause and effect has 
not yet been fully clarified. 56 
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 There are some factors that have not yet been scientifically clarified, namely 
diets rich in red and processed meats and low in fruits and vegetables, physical inactivity, 
coffee, and alcohol, in which recent studies have shown a link between overuse of alcohol 
and pancreatic cancer, although nothing is definitive at this time. It is only known that 
alcohol abuse can lead to chronic pancreatitis and cirrhosis, which are known risk factors 
for this type of cancer. Pancreatic cancer is also more common in type II diabetic people, 
but the reason is still unknown. In relation to risk factors that are not changeable, there 
are several, such as age, in which the upper risk in age > 45 years, gender, where the risk 
is slightly higher in men than in women and race in that African-americans are more 
susceptible than Caucasians. 50 
 Genetics and family history of disease are also risk factors that are not alterable 
and are very supported by the literature. About 5% to 10% of pancreatic cancer patients 
have a family history of the disease. Individuals with the BRCA2 mutation who are at 
increased risk of developing breast and ovarian cancer are now recognized as having a 
greater susceptibility to developing pancreatic adenocarcinoma. 57,58 
 In addition to these genes, there are others with variants associated with 
increased risk of pancreatic cancer, such as BRCA1, MLH1, MSH2, PRSS1 (associated 
with familial pancreatitis), STK11, PALB2, ATM, CDKN2A, APC, MSH6 and PMS2. 
56 
 In general, pancreatic cancer develops without any specific early sign or 
symptom, and any manifestation will depend on the location of the tumor within the 
gland. Approximately 50% of patients have jaundice, which is more common when the 
tumor is in the head of the pancreas, due to obstruction of the adjacent biliary system. 50 
 Apart from this, there are others such as abdominal discomfort, nausea, and 
weight loss. When tumors metastasize to other organs, duodenal obstruction, 
gastrointestinal bleeding, and obstruction of the pancreatic duct may result in steatorrhea. 
Hyperglycemia and diabetes mellitus have been more associated with early 
manifestations of the disease. Patients with advanced pancreatic cancer may also present 
ascites, pain, and depression. Following the most frequently encountered analyzes are 
liver function, hyperglycemia, and anemia. 57 
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2.5 Epidemiological data: in Portugal and worldwide 
 
 Pancreatic cancer is one of the leading causes of death in developed countries 
and one of the most lethal causes worldwide. Based on data provided by GLOBOCAN in 
2012, this type of cancer causes more than 330,391 deaths per year (4.0% of all deaths) 
and is ranked as the 7th leading cause of cancer death in both sexes. The estimated 5-year 
survival rate is less than 5%, and the incidence and mortality correlated with increasing 
age were more common in males (> 25%) than in females. In 2018, the number of deaths 
increased to 432,242 (4.5%) according to GLOBOCAN (Figure 4). 34,35,59 
 
  
 
 
 
 
 
 
Figure 4. Estimated number of cancer deaths, worldwide, both sexes, all ages (2018) 
Source: WHO. 59 
 
 In recent decades, pancreatic cancer-related mortality has increased in both 
developed and developing countries, such as Europe, the United States, Japan, and China. 
The incidence of pancreatic cancer varies greatly across regions and populations, with the 
highest rates in 2012 being recorded in North America (7.4 per 100,000 people) and 
Western Europe (7.3 per 100,000 population). On the other hand, the lowest rates were 
Risk factors Signs & Symptoms 
Smoking Abdominal discomfort Hardened stools 
Age (>45) Weight loss Diabetes 
Diabetes Nausea Ascites 
Obesity Jaundice Mid-back pain 
Chronic pancreatitis Indigestion Depression 
Table 3. Risk factors, signs, and symptoms of pancreatic cancer. 
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recorded in Central Africa and South and Central Asia (1.0 per 100,000 people). This is 
since the latter are developing countries and people often do not have access to health 
care because they are sick before they die. 60–62,63  
 About 55.5% of the new cases were registered in the more developed countries, 
and about 41.0% were recorded in Asian countries.34 According to a study conducted 
between 2010 and 2014 in the United States, the incidence rate of new cases increases 
with age, being higher above 65 years (27.8%). In that same study, a prevalence of 64,668 
people living with pancreatic cancer was recorded in the United States, where the 
estimated 5-year survival rate was about 8.2%. 62,64 
 In Portugal, the number of deaths from pancreatic cancer in both sexes was 
around 4% in 1983 and 5.3% in 2013. In 2018, the estimated number of deaths from 
pancreatic cancer in both sexes is about 5.5% (Figure 5). It was found that, despite 
medical and scientific advances, this cancer remained highly lethal. 65,66,67 
  
 
Figure 5. Estimated number of deaths in 2018, Portugal, all cancers, both sexes, all ages. 
Source: WHO. 67 
 
 2.6 Diagnosis 
 
 In addition to the physical examination, imaging tests may also be done to look 
for areas suspected of having cancer, to determine if the tumor is localized or if it is 
already metastasized, in evaluating the efficacy of treatment, as well as looking for signs 
of cancer recurrence after treatment. Within the imaging tests we have computed 
tomography that allows detailed cross-sectional images to be obtained after the injection 
of intravenous (IV) contrast and is widely used in the diagnosis of pancreatic cancer 
because it shows the injured organ in a very clear way. This is an excellent imaging test 
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to see if surgery can be a good therapeutic option. When a pancreatic tumor is suspected, 
a needle biopsy is performed using endoscopic ultrasound to guide the needle to the 
specific site, although computed tomography can also be used, but it is not as usual. 39 
 Another imaging test that can analyze the pancreatic ducts is called 
cholangiopancreatography. This test aims to assess whether the ducts are blocked, 
narrower or dilated due to the presence of a tumor. Somatostatin receptor scintigraphy 
may be very useful for finding pancreatic neuroendocrine tumors. Positron emission 
tomography (PET) is performed through an injection containing a slightly active form of 
sugar, which has affinity mainly with cancer cells. A specific camera is used to create an 
image of areas of radioactivity in the body. This imaging test is sometimes used to look 
for spread of exocrine pancreatic cancer. Since the NETs grow slowly, they do not present 
well in PET examinations. 68 
 Finally, angiography, another imaging test, is a test that aims to evaluate blood 
vessels. A small amount of contrast dye is injected into an artery to delineate the blood 
vessels and then taken to x-ray. This method of diagnosis can demonstrate whether blood 
flow in a specific area is blocked or compressed by the presence of a tumor. It may also 
show abnormal blood vessels. This test may be helpful in assessing whether pancreatic 
cancer has grown through the walls of certain blood vessels. 68 
 In addition to imaging tests, it is critical that blood tests be done to help with 
more accurate diagnosis or to determine treatment options. If pancreatic cancer is in the 
exocrine part, then hepatic function tests (bilirubin levels) are performed. In addition to 
this, tumor markers can also be searched for in the blood, with CA 19-9 (most common) 
and carcinoembryonic antigen (CEA) being the most commonly identified in this type of 
cancer. However, these tumor marker tests are not elevated in all people with pancreatic 
cancer, and some people who do not have pancreatic cancer may have elevated levels of 
these markers for other reasons. This examination alone is not decisive.50 
 For pancreatic neuroendocrine tumors, blood tests are carried out to evaluate 
pancreatic hormone levels, namely insulin, gastrin, glucagon, somatostatin, pancreatic 
polypeptide, and vasoactive intestinal peptide. In addition, the levels of chromogranin A 
(CgA) and glucose and c-peptide (for insulinomas) can still be evaluated.69 
 In carcinoid tumors, a blood test can be performed to look for the existence of 
serotonin, produced by many of these tumors. Urine can also be tested for serotonin and 
related chemicals, such as 5-HIAA and 5-HTP. All the previously mentioned methods 
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may suggest that there is pancreatic cancer, but generally the only way to be sure is to 
remove a small sample from the tumor and to analyze it microscopically. This process is 
called a biopsy and can be performed in different ways such as through the skin 
(percutaneous), endoscopic (endoscopic) or surgery (surgical), the latter being less 
frequent these days.39 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Computed tomography scan of a 73 year old male patient with pancreatic cancer in the 
pancreas head with about  3 cm (arrow). 70 
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Chapter 3. Conventional treatment of pancreas cancer 
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3.1 Chemotherapy 
 
 Systemic chemotherapy is used to alleviate symptomatology and prolong the 
survival rate of patients. However, metastatic pancreatic tumors are highly 
chemoresistant, with response rates to multiple chemotherapeutic agents, such as 
antimetabolites, alkylating agents, antibiotics, and anthracyclines, in monotherapy and 
combination therapy, less than 20%. Gemcitabine replaced 5-fluorouracil as a first-line 
treatment for metastatic pancreatic cancer because the overall survival time was higher 
and clinical improvements in the main common symptoms, namely, pain, functional 
impairment, and weight loss. However, gemcitabine only provides a 6-week increase in 
mean survival, ranging from 4.5 months to 6 months. 71 
 Currently, this drug is used not only in monotherapy but also in combination 
therapy with other chemotherapeutic agents, i.e., antimetabolites (fluorouracil, 
pemetrexed), topoisomerase I inhibitors (irinotecan, exatecan), platinums (cisplatin, 
oxaliplatin) and taxanes (paclitaxel, docetaxel). 72 
 A phase III clinical trial demonstrated that adding oxaliplatin to gemcitabine 
resulted in an increase in response rate and progression-free survival, providing clinical 
benefits. However, it failed to demonstrate a higher overall survival rate. Another phase 
III clinical trial demonstrated that the addition of erlotinib (epidermal growth factor 
receptor 1 inhibitor (EGFR1) to gemcitabine provided a 1-year survival rate (23% vs 
17%) compared to gemcitabine monotherapy. 73,74 
 In 2011, FOLFIRONOX, a combination of 5-FU, leucovorin / folinic acid, 
oxaliplatin and irinotecan, demonstrated a superior survival rate in patients with 
pancreatic cancer, compared to gemcitabine as sole agent, which led to the adoption of 
this drug as therapy of choice in this type of cancer. However, the toxicity profile was not 
inconsequential, demonstrating an increased risk of myelosuppression, fatigue, vomiting, 
diarrhea, and thrombocytopenia. For this reason and even though this drug has improved 
the overall survival rate, it remains low, more effective, and effective treatments are 
needed for the treatment of pancreatic cancer. 72,75 
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3.2 Radiotherapy 
 
 Radiotherapy is often used in combination with systemic chemotherapy, 
offering no benefit alone after pancreatic cancer surgery. However, a randomized phase 
III study showed that patients benefited more from the combination of chemotherapy and 
radiotherapy than with isolated chemotherapy alone. 76,77 
 Radiotherapy has a substantial advantage over local control and improves the 
rate of resectability after downstaging. However, mean survival rates do not improve in 
patients with non-resectable pancreatic cancer. A novel and specific technique called 
stereotactic radiotherapy, which uses imaging guidance to deliver toxic radiation in direct 
doses to tumors, has shown partially improved survival outcomes. However, in 
comparison to tumors, the overall survival of patients with pancreatic cancer is still 
unsatisfactory, as is the toxicity associated with this treatment method, and further studies 
are needed to determine the role of radiotherapy in resectable pancreatic tumors. 78 
 
3.3 Hormonal therapy 
 
 Somatostatin and its analogues, peptide hormones, can act as inhibitors of tumor 
cell growth, by triggering signal transduction, which negatively controls cell growth, or 
through downregulation, responsible for tumor growth. 79  
 Szende et al. demonstrated that somatostatin can induce tumor regression 
through a mechanism of cell death program. 80  
However, somatostatin monotherapy has no therapeutic benefit in the treatment of 
pancreatic cancer. Ebert et al. demonstrated that using a somatostatin analogue called 
octreotide (at high dose), the median survival in patients with advanced pancreatic cancer 
was 6 months, compared to the low dose which was only half. 81,82 
 In addition to somatostatin and its analogs, estrogens may also be used in the 
treatment of this type of cancer, since pancreatic carcinomas have estrogen receptors. 
Rosenberg et al. reported that patients receiving a combined octreotide-tamoxifen 
regimen demonstrated an average survival benefit (12 months) compared to 
monotherapy. 83,84 
 The use of leuprolide (Lupron), a luteinizing hormone agonist, alone or in 
combination with somatostatin, demonstrated in vitro and in vivo activity in hamsters 
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with pancreatic cancer. With these results, Zaniboni et al. performed a phase II clinical 
trial where they tested the leuprolide-tamoxifen combination, but the results were 
disappointing, achieving only a mean survival of 5 months. In short, the impact of 
hormone therapy on this type of cancer is quite limited. 85–87 
 
3.4 Immunotherapy 
 
 The use of this therapy has been growing considerably, particularly in 
pancreatic cancer. The microenvironmental immunosuppressive tumor in pancreatic 
cancer is an important regulator in the process of disease progression and is responsible 
for the ineffectiveness associated with conventional therapy, i.e. resistance to 
chemotherapy. Usually includes a fibrotic stroma that has a considerable stromal density 
and acts as a barrier that prevents the delivery of cytotoxic drugs, also limiting the access 
of T cells to tumor cells. 88,89 
 In addition, extensive infiltration of myeloid cells composed of macrophages 
and immature / suppressor myelogenous cells derived from myeloid cell derivatives 
(MDSCs) accumulated during the progression of pancreatic cancer can lead to T cell 
dysfunction. Thus, depletion of macrophages or MDSCs results in the increased 
infiltration and activation of CD8+ T cells, improving the fight against tumor cells. 89,90  
Zhang et al. concluded that myeloid cells are necessary at multiple stages of pancreatic 
carcinogenesis, and therefore, depletion of myeloid cells during the development of 
pancreatic cancer can prevent the formation of tumors. 90 
 These authors also identified that myeloid cells act as conductors of immune 
check-point ligand PD-L1 expression in tumor cells by the activation of epidermal growth 
factor / mitogen-activated protein kinases signaling. PD-L1 is an immuno-inhibitory 
molecule that suppresses T-cell activation, leading to tumor progression. Thus, by 
inhibiting MAPK, tumoral vulnerability can be increased by PD-1 / PD-L1 blockade and 
may be a new therapeutic approach in the treatment of pancreatic cancer. 89,90  
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3.5 Surgery 
 
 There are two types of surgery for pancreatic cancer. Potentially curative 
surgery, which is used when the results of diagnostic tests suggest that removal or 
resection of the entire tumor is possible, or palliative surgery that can be performed if 
imaging tests show that the tumor is too widespread to be completely removed. The latter 
is used to relieve symptoms or to prevent certain complications, such as blockage of the 
bile duct or intestine, and is not a surgery with a curative potential. However, since most 
cases of pancreatic cancer are only diagnosed when metastases already exist, that is, in 
stage IV, the resection surgery does not apply, since the cancer is no longer limited to the 
pancreas.72 
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Chapter 4. Nanomedicine  
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4.1. Definition, advantages and disadvantages 
 
 Nanomedicine is defined as the application of nanobiotechnology to medicine, 
based on the use of materials and devices at the nanoscale for diagnosis and delivery of 
drugs. In addition to these applications, nanobiotechnology is also being developed for 
the implementation of nanosurgery. Such a technological advance can be useful for 
nanoscale systems administration the human body and detect or treat various pathologies. 
91 
 Over the last decade, extraordinary progress has been made in the application 
to cancer, which is currently the most important pathology in nanomedicine investment. 
Nanobiotechnology plays a pivotal role in the discovery of tumor biomarkers and several 
drugs are being developed for the treatment of various types of cancer, some of which are 
already approved. 92 
 Applying nanomedicine to the treatment of pancreatic cancer, the subject of this 
dissertation, there are numerous advantages compared to conventional therapies. These 
advantages relate to controlled and sustained release of drugs; lower systemic toxicity, 
since the delivery of the drug is directed, through the conjugation of ligands on the surface 
of the nanoparticles; reduced number of administrations, as there is an increase in drug 
time and concentration at the local level; and better stability and anticancer activity. 93 
 One of the major problems for the ineffectiveness of pancreatic cancer 
treatments is that pancreatic tumor cells are resistant to gemcitabine, a pyrimidine 
antagonist, used as a first line treatment in chemotherapy.92  
 Through nanomedicine it may be possible to circumvent this problem by 
increasing the effectiveness of this type of treatment and also by exploring alternative 
therapies. 94 
 Nanoparticles have dimensions 100 to 10000 times smaller than human cells 
and can remain stable in physiological environment and passively maintain the target in 
pancreatic tumor cells through increased permeability and retention effect, which is due 
to their size, causing them to leak out of blood vessels, and to attach to the carcinoma. 8  
 However, they are not only advantages. Its non-physiological chemical surface 
can cause non-specific cellular segmentation and consequently precipitation, which leads 
to the occurrence of cellular damage. 94 
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 Nanoparticles consisting of polymers or natural substances, such as modified 
polyesters, polysaccharides, and proteins (e.g., albumin), have numerous functionalities 
and a promising importance with regard to localized chemotherapy, since they can be 
used to actively target tumor cells through of a combination with specific recognition 
elements, such as monoclonal antibodies, already used in the treatment of oncological 
diseases. 95 
The nanostructured materials are processed forms of crude nanomaterials that 
provide specific shapes or with certain predefined functionality, and which are divided 
into polymers, such as dendrimers, micelles, etc., and non-polymers, such as carbon 
nanotubes, metal nanoparticles, among others (Figure 7). 96 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
        Silica nanoparticle 
 
 
Figure 7. Types of nanoparticles for drug delivery in cancer therapy. 96 
 
 
4.2 Methods of preparation of nanoparticles 
 
 The method used in the preparation of nanoparticles and the choice of the ideal 
polymer are dependent on the physicochemical properties of the drug to be encapsulated, 
as well as the intended release characteristics of the therapeutic target, the route of 
administration for which it is intended, biocompatibility the particle and the delivery 
system. 97 
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 The choice of these conditions is modeled by the possibility of achieving a high 
encapsulation efficiency, a high yield of the product and an easy scale-up.  There are 
several methods of preparing nanoparticles, which fall into two main types: “bottow-up”, 
in which nanoparticles are formulated according to their molecular size, and “top-down” 
where physic-chemical methods are applied. 98,99  
 
 
 
 
 
 
 
Figure 8. Methods of nanoparticles production; 100 
 
Polymeric nanoparticles are the most studied model in the pharmaceutical field, 
which allowed their greater development with respect to the preparation methods. These 
can be classified into two groups, and their classification depends on the fact that the 
nanoparticles are formed simultaneously to the polymer, which requires polymerization 
reactions, or to be obtained directly from a preformed polymer. 98,101 
The first group, where polymerization reactions are required, comprises the 
methods of emulsion polymerization (nanosphere formation), interfacial polymerization 
and interfacial polycondensation, the first being quoted the fastest 98,101 
The emulsion polymerization method is divided into two categories, distinguished 
using continuous organic or aqueous phases. In the case of a liquid phase, the monomer 
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is dispersed with agitation in a continuous phase in which it is immiscible and can be 
made in systems without emulsifier or oil-in-water or water-in-oil emulsions. 98,101 
Interfacial polymerization includes distinct phases of preparation where the 
monomer is added in an oil phase of a previously prepared microemulsion, very useful 
when it is desired to encapsulate highly water-soluble molecules, such as peptides and 
nucleic acids, and in the formation of nanocapsules. Interfacial polycondensation is also 
used in the formation of polymeric nanoparticles, with the aid of a lipophilic monomer in 
the presence or absence of a surfactant.98 
The second group, where the nanoparticles is obtained from a preformed polymer, 
may be previously formed synthetic, using solvent emulsification / evaporation methods, 
solvent nanoprecipitation or interfacial deposition, solvent emulsification / diffusion and 
salting-out. The solvent emulsification / evaporation method consists of two phases, 
wherein the first comprises the emulsification of the polymer in an aqueous phase, and 
the second comprises the evaporation of the solvent, which induces the formation of 
nanospheres by precipitation of the polymer. 101 
Nanoprecipitation involves the precipitation of a preformed polymer into an 
organic character solution, and then diffusion of the organic solvent into aqueous medium 
in the presence or absence of a surfactant, which results in polymer precipitation into 
nanospheres. The solvent emulsification / diffusion method involves the dissolution of a 
polymer in partially water miscible medium and simultaneously saturated therein. 101 
 
 
 
 
 
 
 
Figure 9. Preparation of nanoparticles by nanoprecipitation method. 101 
 
The salting-out method is a change from the above-described method since it 
comprises separating this partially miscible water solvent from the aqueous solution 
through salting-out, where the polymer is dissolved in the organic solution (oil phase), 
generally miscible in water and the aqueous phase is comprised of surfactant and a 
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solution saturated with an electrolyte (for example, the magnesium acetate tetrahydrate 
normally used in a ratio of 1:3 (polymer to salt)), which should not be soluble in the 
organic solvent. The oily phase is emulsified in the aqueous phase by a strong shear force 
through a mechanical overhead stirrer. In summary, the difference between the two 
methods is that in the latter there is no solvent diffusion stage due to the presence of the 
electrolyte. 101,102 
 
 
    
 
 
 
 
 
 
 
 
 
4.3 Nanoparticles for pancreas cancer treatment 
 
In recent years, much has been done to improve not only the quality of life, but 
also to extend the life span of pancreatic cancer patients. There are numerous 
nanotechnology-based formulations with chemotherapeutic agents already known in 
different phases of clinical trials, and some of them already in phase III, close to being 
approved and marketed.92  
The future of pancreatic cancer treatment also undergoes interference-based RNA 
(iRNAs) therapy. This therapy is progressing, proving to be a viable alternative in relation 
to conventional treatments, about the specificity, the toxicity, and the overcoming of 
existing resistance to numerous drugs. RNAi is an endogenous process that acts by 
silencing the genes that can cause any type of degradation of the mRNA once the RNA 
sequence used is known. SiRNAs have been assigned to ensure propagation both in vitro 
and in vivo. SiRNAs are involved in the silencing of post-transcription genes for specific 
mRNAs. The RNA-induced silencing complex acts as a guide to cleave mRNAs through 
Figure 10. Preparation of nanoparticles by salting-out method; 102 
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a sequence complementary to siRNA and can be recycled repeatedly to cleave additional 
mRNAs. 103,104 
 It is important to note that the introduction of chemically synthesized siRNAs 
into the cell may give rise to the activation of this previously described process, which 
may be useful as a gene therapy to suppress specific genes associated with various 
pathologies. However, the vectorization of siRNA into the target cell still represents an 
obstacle to this innovative therapy, mainly due to the administration of siRNA in vivo, 
because it presents lack of stability and vulnerability to degradation, due to its highly 
negative (anionic) charge. 105  
 However, nanoparticles in the form of liposomes, lipid polymers and 
dendrimers may be the key to this problem. These delivery systems can encapsulate the 
siRNA, protecting it from degradation and elimination by the immune system, as well as 
delivering the same to the specific target cell. 106,107,108 
 Thus, in this chapter, nanoparticles will be addressed as well as the means of 
delivery of already known drugs, such as lipid nanoparticles, polymer nanoparticles, 
metallic nanoparticles, or magnetic nanoparticles, as well as delivery systems that can 
encapsulate siRNA, as previously mentioned. Both methods have increasingly been 
shown to be the future in the treatment of pancreatic cancer. 
 
4.3.1 Lipid nanoparticles 
 
 Among the various lipid formulations based on nanotechnology, the most 
widely used liposomes are extensively studied. However, they are not the only ones. 
Lipoplexes, (lipid-based assemblies of non-covalently associated charge-load 
interactions) are used in genetic targeting studies. 109 
 The following sub-chapters will address examples of lipid nanoparticle types 
drug delivery medium as well as siRNA. 
 
4.3.1.1 Liposomes 
 
Liposomes are small spherical particles consisting of one or more phospholipid 
bilayers with an internal hydrophilic compartment through the introduction of 
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phospholipids in aqueous solution. Depending on the design, they can vary between 10 
nm and micrometers. The use of liposomes for delivering drugs has had a huge impact on 
medicine. Drugs with high toxicity or low bioavailability benefited from the stabilization 
and biodistribution added by the liposomes. 75,110 
A study in which the efficacy and safety of nanoparticles of liposomal cisplatin 
(lipoplatin) conjugated to gemcitabine in patients with pancreatic refractory cancer was 
established, demonstrated that there was a partial response (increase of 50% reduction in 
the sum of products of the diameters perpendicular lesions lasting at least four weeks) 
and that the mean survival from the start of treatment was four months. The bi-weekly 
dose of treatment was 100mg/m2 of lipoplatin and 1000mg/m2 of gemcitabine and was 
well tolerated without evidence of neurotoxicity or nephrotoxicity. A liposomal 
formulation containing Raf-1 antisense oligonucleotides also demonstrated improved 
antitumor activity against human pancreatic tumors in an athymic mouse model. 111  
 
4.3.1.2 Modified liposomes 
 
 A study realized in 2006 reported the therapeutic potential of the nanoparticles 
complexed with siRNA. In this study, the authors used PEG-modified liposomes and 
contained on their surface-active targeting moieties to improve tumor bioavailability. 
These modified liposomes were to be administering apoprotein B siRNA to non-human 
primates. Single administration at systemic level resulted in a significant reduction in 
mRNA and apoprotein B (apo B) protein expression as well as a reduction in total 
cholesterol. In this study it was also possible to determine that the complex formed by the 
modified liposome and siRNA was non-toxic and allowed the sustained blockade of apo 
B for 11 days. 106 
 These complexes were also used in another study to carry the siRNA so that it 
is mutated into a gene involved in promoting the aggressive growth of orthotopic liver 
tumors. Together, the results of these studies highlight the therapeutic potential of the use 
of nanoparticle-siRNA complexes in the treatment of human diseases. 112 
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4.3.1.3 Cationic lipid polymers 
 
 The advantage of using cationic lipid polymers to deliver siRNA stems from 
their ability to traverse the cell membrane, promote leakage of the endosomal 
compartment and target genes with good biocompatibility. However, there are also 
drawbacks. As the induction of a response by interferon and may occur undesired 
interactions with negatively charged serum proteins. Cationic lipid polymers can interact 
with negatively charged siRNA through ionic interactions. Thus, the self-assembled 
lipoplexes confer protection to the siRNA, preventing it from undergoing enzymatic 
degradation, increasing its cellular uptake by endocytosis, increasing the release of 
siRNA from the endosomal/lysosomal compartment, and promoting its accumulation in 
the cytosol. 108 
 Currently there are various formulations of commercially available cationic 
lipid polymers, such as Lipofectin®, Lipofectamine® (Invitrogen), Dharmafect® 
(Dharmacon®), RNAifect® (Qiagen) and TransIT TKO® (Mirus). These formulations 
were studied as transfection reagents for in vitro administration of siRNA, and it was 
concluded that the lipid / siRNA ratio affects the colloidal properties of lipoplexes (size 
and zeta potential), facilitates the cellular internalization of lipoplexes and dissociates 
nucleic acids in the cytosol. 113 
 
4.3.1.4 Liposomes conjugated to antibodies or peptides 
 
 Currently, nanoparticles conjugated to antibodies or peptides with the goal of 
targeting the siRNA to target cancer cells have been the goal of many investigators. 108 
The transferrin receptor (TfR), folate receptor and Arginine-Glycine-Aspartic ligands are 
some of the examples of cell surface target receptors used, since there are several studies 
that prove that they are highly expressed in various types of tumors. 114,115 
 Pirollo et al. used liposomes which contained a TfR antibody conjugated to its 
surface, carrying siRNA against HER-2. They compared the use of this same siRNA 
delivery system, compared to one without TfR antibody, and concluded that there was 
greater delivery of siRNA in pancreatic tumors in a murine xenograft model in which TfR 
antibody was contained. In addition, they also concluded that lipocomplex-siRNA had 
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the ability to inhibit HER-2 expression in pancreatic tumor cells and increase sensitivity 
to gemcitabine, a promising advance in the treatment of pancreatic cancer. 116 
 
4.3.2 Polymer nanoparticles 
 
 Nanoparticles based on natural polymers are usually biocompatible, 
biodegradable, and non-toxic, although there are often stability problems when delivered 
to the various biological membranes. Within natural polymers, chitosan, gelatin, albumin, 
and alginate are the most commonly used. However, synthetic polymers may also be used 
in the form of a preformed polymer, and polyesters such as polycaprolactone (PCL), poly 
(lactic acid) (PLA) or monomers that can be polymerized in situ. There are a few 
advantages in using such nanoparticles in drug delivery, such as biocompatibility, 
increased stability of any less toxic volatile pharmaceutical agent, are readily 
manufactured in large quantities, non-immunogenicity, and non-toxicity, among others. 
117 
 Polymeric nanoparticles can be vesicular systems (nanocapsules) or matrix 
systems (nanospheres). Nanocapsules are systems in which the drug is confined to a 
cavity surrounded by a single polymer membrane. Nanospheres are systems in which the 
drug is dispersed by a polymer matrix. Within polymer nanostructures beyond polymer 
nanoparticles, there are dendrimers, micelles, and conjugated drugs. 118 
 In the next subchapter we will cover micelles, albumin nanoparticles, and 
dendrimers, three types of polymer nanoparticles used in clinical trials under development 
for the treatment of pancreatic cancer. 
 
4.3.2.1 Micelles 
 
 An example of polymeric nanoparticles is the micelles, consisting of PEG as the 
hydrophilic compound and the hydrophobic modified polyaspartate which binds the drug. 
Paclitaxel, an antimicrobial chemotherapeutic agent used in solid tumors, has limited 
efficacy due to its poor water solubility. Using a micelle formulation, it was possible to 
overcome this limitation of paclitaxel by encapsulating it into the micelle which is water 
soluble. This study concluded that with this formulation it was possible to achieve 
improved antitumor activity due to the EFR effect. 119 
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 Hamaguchi et al. conducted a phase I clinical trial to determine the maximum 
tolerated dose, dose-related toxicity, and pharmacokinetics of NK105, a micellar carrier 
system for paclitaxel delivery. Pancreatic cancer patients receiving IV infusion of NK105 
were recruited, and the results were encouraging. The patients well tolerated this system, 
and none of the patients developed significant hematological toxicity. A partial response 
was seen in a patient with metastatic pancreatic cancer, who received 150 mg/m2, but 
only in hepatic metastases (reduction in size of 90%), but the effect on the pancreas was 
not reported specifically. 120 
 
4.3.2.2 Albumin nanoparticles 
 
 Albumin is a carrier protein with broad interest in drug delivery as it is 
biocompatible, biodegradable, non-toxic and non-immunogenic. Many authors consider 
it an ideal material for producing nanoparticles for drug delivery. The accumulation of 
albumin nanoparticles can occur either by passive (active EPR) or active segmentation, 
due to the high affinity with cellular receptors overexpressed in tumor cells. 121 
 Significant amounts of drug can be encapsulated in its matrix, since there is a 
high number of binding sites present in the albumin molecule. This protein can also 
improve the solubility of lipophilic drugs. The conjugation between a compatible and 
specific ligand and the surface of the albumin nanoparticle, confers active cleavage and 
enables target delivery to a receptor present in the target cells, by covalent attachment.122 
 A phase I / II study for pancreatic cancer demonstrated the maximum tolerated 
dose for Nab-paclitaxel (paclitaxel-linked albumin nanoparticles) combined with 
gemcitabine. The authors also reported a better overall survival (12.2 months) compared 
to gemcitabine alone. 14 
 Another phase III clinical trial for metastatic pancreatic adenocarcinoma 
demonstrated that the addition of Nab-paclitaxel to gemcitabine not only significantly 
improved mean survival (8.5 months) compared to treated patients with gemcitabine 
alone (6.7 months) which significantly reduced neuropathy and neutropenia, associated 
with cremaphor used to dissolve paclitaxel, which allows a higher dose of paclitaxel 
administered. 123 
 Some authors constructed multifunctional albumin nanospheres (called C225-
GEM / MANs), where albumin acted as an outer shell, while the inner core imprisoned 
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magnetic nanoparticles of Fe3O4 conjugated to gemcitabine. The anti-EGFR mab C225 
functioned as an active agent that directed the delivery system to the target site. 124 
 
4.3.2.3 Dendrimers  
 
 Dendrimers are highly branched macromolecules, and the functional groups 
present on their surface can be modified to increase biocompatibility and decrease 
toxicity. It is possible to complex them with siRNA through electrostatic interactions, 
such as polycyclic dendrimers (polyamidoamine (PAMAMs) or polypropyleneimine 
(PPI)), which have a high density of positive charges to their surface. For PAMAMs, 
which have primary amine groups on their surface and tertiary amine groups within them, 
they can complex with siRNAs. Thus, the complex formed promotes the cellular uptake 
of siRNA and the tertiary amine groups initiate the proton sponge effect, to increase the 
endosomal release of siRNA. 125 
 The in vitro characterization and anti-cancer effect of siRNA delivered by 
PAMAM dendrimers against human telomerase reverse transcriptase (hTERT) was also 
done in mouth cancer. Liu et al. concluded that siRNA-hTERT dendriplexes, applied by 
intratumoral administration, inhibited cell growth and apoptosis in vitro, as well as 
inhibited tumor growth in vivo in the xenograft model. It also found that there was a 
decrease in the expression of hTERT proteins in tumors. 126 
 
4.3.3 Magnetic nanoparticles 
 
 Magnetic nanoparticles are part of a group of materials based on 
nanotechnology with a strong impact in the fields of analytical chemistry, biomedicine, 
and bioengineering. These nanoparticles came to aid in the diagnosis and treatment of 
various pathologies, the magnetic separation of biological entities contributed to the 
development of diagnoses, the magnetic nano delivery systems contributed to the release 
of drugs, while the magnetic nanoparticles controlled by radiofrequency came to provide 
a new approach to treatment of cancer. 127 
 The only limitations of this type of nanoparticles are biocompatibility and 
immunogenicity, but both can be controlled by suitable coatings of particles. 
Iron oxide nanoparticles represent significant advantages such as price, since they are 
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cheap to produce, physical and chemical stability, biocompatibility, and are 
environmentally safe. 128 
 The use of this type of nanoparticles for the treatment of pancreatic cancer is 
discussed in the next subchapter. 
 
  4.3.3.1 Iron oxide nanoparticles 
 
 The most widely used iron oxide magnetic nanoparticles are iron oxide in the 
core surrounded by a biocompatible surface coating that demonstrates stability in the 
physiological environment. With the ligation of functional ligands to the surface of the 
nanoparticle, a greater functionality of the nanoparticle is possible, namely the 
vectorization of a drug to a target cell.  Several studies have already been carried out in 
which the surface of nanoparticles of iron oxide was modified using cytotoxic drugs, such 
as doxorubicin (DOX), catechin-dextran and paclitaxel. 94 
 The study in which they conjugated catechin-dextran nanoparticles to 
Endorem® (FDA approved drug) demonstrated that there was an increase in the 
intracellular concentration of the drug compared to the free drug. This formulation was 
placed in a human pancreatic cancer cell line (MIA PaCa-2) under a magnetic field and 
caused 98% apoptosis. These results were suggestive that this conjugation enhanced the 
antitumor activity of Endorem® and provided a novel delivery system specific for cell 
tumors driven by magnetic fields.94 
 
  4.3.3.2 Gold nanoparticles 
 
 The three most important properties of the gold nanoparticles that aroused the 
researchers' interest were that they were easily prepared, had low toxicity, and easily 
conjugated to molecules of biological interest. A clinical trial using CYT-6091 (colloidal 
gold nanoparticles with surface-bound recombinant tumor necrosis factor and PEG) in 
patients with advanced solid pancreatic tumor has been shown to selectively target tumor 
tissue. There were, however, associated adverse effects, such as lymphopenia, 
hypoalbuminemia, electrolyte disturbances, and disorders in liver enzymes, but not very 
marked. This study did not specify any overall survival. These results suggest that the 
CYT-6091 formulation selectively targets pancreatic cancer, which may be beneficial in 
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delivering chemotherapeutic agents, but further studies are needed to specifically 
understand the effect in terms of survival. 92 
 In another study the gold nanoparticles have been shown to be biologically 
viable and highly adaptable for conjugation to any compound having a high functionality. 
Conjugating gold nanoparticles with gemcitabine demonstrated that there was significant 
inhibition of pancreatic cancer cell growth in vivo and in vitro with virtually no toxicity.3 
 
4.4 Toxicity problems  
 
 The toxicity associated with this type of delivery system may occur due to the 
composition, size, or load of the nanoparticles. In general, the particles of smaller 
dimensions present greater toxicity in relation to the larger ones, the comparison being 
made when they have the same chemical and crystalline structure and composition. 
However, very small particles are less efficient because the clearance system more easily 
removes them. 129,130 
  The main concerns related to NPs are the fact that they are carcinogenic. Often 
the encapsulated or encapsulating material causes increased production of reactive 
oxygen species (ROS), which can lead to mutations in the DNA. There are also reports 
that exposure to nanoparticles is associated with asthma, bronchitis, Alzheimer's disease, 
and Parkinson's. Several events related to vascularization, such as blood clots, are 
associated with nanoparticles administered parenterally. Cationic liposomal nanoparticles 
can interact with the extracellular matrix, serum proteins and lipoproteins, with resulting 
aggregation and / or oxidative stress that can cause non-target tissue damage.131  
 The metallic nanoparticles have a large surface due to their size, low surface 
charge at physiological pH, and easily aggregate in solution due to their inherent metallic 
character. In some cases, aggregation is a concern because it can decrease long-term 
stability.132 
 The accumulation of dose-dependent silver nanoparticles was observed in the 
brain and other organs, suggesting a systemic distribution after oral administration. There 
was also a significant increase in ALP and cholesterol indicating hepatotoxicity. 130 
 Gold nanoparticles can cross the placenta and cause damage to fetal 
development but are also involved in the induction of reactive oxygen formation and 
initiation of autoimmunity. 133,134 
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 Since there are several materials used in the construction of nanoparticles, there 
are an infinite number of combinations of interactions with a high potential for harmful 
interactions that must be studied and considered to ensure the life and well-being of 
patients.  
 
4.5 Walkthrough on pipeline products 
 
 About 150 drugs under development are based on nanotechnology. Some of 
them are already approved and the rest are in the various stages of development. 91  
 In 1995, research around liposomes resulted in the first approved drug of Doxil® 
by the US Food and Drug Administration (FDA). In January 2012 there were 33 more 
approved nano-drugs and marketed worldwide. 135,136 
 In liposomes, in addition to Doxil®, which is based on doxorubicin 
hydrochloride encapsulated in stealth liposomes (100 nm), consisting of N- (carbonyl-
methoxypolyethylene glycol 2000) -1,2-distearoyl-sn-glycero-3-phosphoethanolamine 
sodium phosphatidylcholine, fully hydrogenated soy phosphatidylcholine and 
cholesterol, and which has multiple myeloma and ovarian (IV) cancer as a therapeutic 
indication, other nano-drugs have been approved. More recently, in 2012, Marqibo®, 
vincristine was encapsulated in sphingomyelin / cholesterol liposomes (100nm) (60/40, 
molar, and it was indicated in the treatment of acute lymphoblastic leukemia. 135,137 
 In 2015, FDA approved a nanoliposomal formulation of irinotecan called 
Onivyde®. It is an indicated topoisomerase I inhibitor, in combination with (5-FU) and 
leucovorin, for the treatment of metastatic pancreatic cancer following gemcitabine-based 
therapy. 138,75 
 There are other nanoformulations based on polymers approved by the FDA. 
Among them Eligard®, approved in 2002, classified as nanoprotectic when evaluated by 
the same criteria applied to liposomes. This nanoproduct is based on nanoparticles 
composed of PLGA (DL-lactide / glycolide; 1/1, molar) copolymer incorporated with 
leuprolide acetate, a synthetic analogue of GnRH or LH-RH, used in advanced prostate 
cancer. 139 
 In 2012, Opaxio® was approved and it consisted of solid nanoparticles 
composed of polyglutamate covalently bound to paclitaxel, indicated for glioblastoma. It 
acts by releasing the antineoplastic drug within the solid tumor by the enzymatic 
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hydrolysis of the polyglutamate and is another example of a polymer-based 
nanoformulation. 137 
 Another example of nano-drugs are the drug-protein conjugates. One of them is 
Kadcyla®, an immunoconjugate approved in 2013 by the FDA for the treatment of 
metastatic breast cancer. Abraxane®, an example of a drug-protein conjugate consisting 
of albumin-bound paclitaxel, has also been approved by the FDA for use in patients with 
metastatic breast cancer and non-small cell lung cancer (NSCLC). 140,141 
 No less important, metal-based nanoformulations, such as NanoTherm®, 
approved since 2013, are indicated for gliobastoma, prostate and pancreatic cancer 
(intratumoral). It consists of a formulation consisting of nanoparticles of 
superparamagnetic iron oxide coated with aminoasilane. It acts by thermal ablation, 
injecting the nanoparticles exposed to the magnetic field, causing them to oscillate, thus 
generating a heat wave directly inside the tumor tissue. 142 
 Finally, there are virosomes. The world's first genetically-engineered therapies 
were approved in the People's Republic of China and the Philippines. In 2003, 
Gendicine® was approved in the PRC, a recombinant Ad-p53 gene therapy for squamous 
cell carcinoma of the head and neck. 143,144 
 In 2007 in the Philippines, Rexin-G®, described as the "first targeted molecular 
genetic injectable medicine", was approved, blocking the endogenous cyclin G1 protein, 
disrupting the cell cycle. This drug is used for all metastatic solid tumors, unlike the 
previous one, which can’t be used if they are metastatic. 145,146  
 However, there are also drugs that are still in development. One example is 
Thermodox®, which is in phase III, a doxorubicin bound to liposomes, like Doxil®, but 
is formulated with thermal sensitivity lipids that degrade the bilayer when exposed to high 
temperatures. 75 
 Another example is NKTR-102, a PEGylated etirotinotecan drug, which has 
been extended in phase III clinical trials. The results were promising, demonstrating that 
after prolonged exposure of tumor cells to the topoisomerase I inhibitor, the therapeutic 
response was improved. 147 
 Recently a phase I assay was performed with CYT-6091, a recombinant human 
tumor necrosis factor linked to colloidal gold, for the treatment of solid tumors. In this 
assay, rhTNF was conjugated to gold nanoparticles using a biocompatible PEG ligand 
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and it was discovered that the dose of rhTNF administered after gold immobilization 
could be 3 times greater than the isolated rhTNF without causing toxicity. 148 
 Several clinical trials are underway for combination therapies based on 
gemcitabine, a deoxycytidine nucleoside analogue whose antiproliferative properties are 
dependent on various inhibitory actions on DNA synthesis, blocking cell cycle 
progression at the G1 / S phase boundary for treatment of pancreatic cancer. The 
combination of gemcitabine and Abraxane® for stage II pancreatic cancer is in phase II, 
gemcitabine with erlotinib for advanced localized cancer is in phase I, among others. 149 
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5.1 Introduction  
 
 The objective of this experimental study was the development of polymeric 
nanoparticles with specific characteristics that could be used as a therapy for pancreatic 
cancer. 
 The choice of the best production of these nanoparticles was based on the 
possibility of subsequently encapsulating a compound of natural origin named 
Parvifloron D, an abietane diterpene extracted from Plectranthus ecklonii species, 
belonging to the family Lamiaceae.15  
 This interest in the use of this drug has arisen since some studies confirm that 
this diterpene has strong cytotoxic properties against several human tumor cell lines and 
that its antiproliferative effect is generally associated with an increase in the intracellular 
level of reactive oxygen species (ROS) that play a crucial role in the apoptosis process, 
which may be advantageous for promising therapy for pancreatic cancer. Parvifloron D 
is a polymorphic drug and exhibits very low water-soluble characteristics, as well as an 
apparent lack of selectivity for cancer cells.150 
 The delivery of this cytotoxic agent through nanotechnology may be the key to 
a targeted delivery to pancreatic tumor tissue with less undesirable effects. 
 
5.2 Materials and methods  
 
5.2.1 Evaluation of the best nanoparticles producing method  
 
 Parvifloron D has low solubility and lipophilic characteristics, and for this 
reason a biocompatible and hydrophilic nanomaterial was selected, with the main 
objective being to achieve optimized bioavailability and stability. 
 Albumin was chosen as the encapsulating material because this protein has an 
active target and a special activity in the liver-pancreas system and is the most abundant 
protein in the blood plasma. 5,6,151,152  
 It is a biodegradable, non-toxic, non-immunogenic protein, and is very easy 
oncology because of its ability to transport hydrophobic drug molecules under aqueous 
conditions by physical encapsulation. In addition to having a significant role of 
unimproved solubility, this protein can also extend circulation time, stimulate prolonged 
drug release, and accumulate at tumor sites, thereby maximizing therapy and minimizing 
toxicity. 153,154 
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 The albumin nanoparticles can be physically stable, and their negatively 
charged surface allows a homogeneous suspension, thus avoiding flocculation.155 
 Desolvation was the method chosen to produce nanoparticles. This technology 
is suitable for a wide range of polymers, especially those sensitive to high temperature, 
such as albumin. The main advantage of this method is that there is no increase in 
temperature. The last step of this method is the addition of an agent whose function is the 
stabilization of the newly formed nanoparticles, with glutaraldehyde being the most used 
agent. 156,157,158,159  
 However, there is evidence to show that the same have toxic effects such as 
dermatitis and eye irritation and nose, with allergic rhinitis associated. In 2005, the 
cytotoxicity of surgical tape used in the treatment of dissections of the aorta, composed 
by albumin and glutaraldehyde, was studied, and although the glutaraldehyde ensures a 
strong adhesion to tissues and synthetic materials, use it as an agent of reticulation as his 
release, can result in both cytotoxic effects in vitro and in vivo. For this reason, we tested 
alternative crosslinking methods including ultraviolet (UV) radiation, addition of glucose 
and the combination of both.160  
 The crosslinking agent was not the only concern we had in the production of 
albumin nanoparticles. Other conditions were also tested to confirm whether we could 
improve our formulation, excluding the worst-case scenario until we reached the best 
conditions for the formation of BSA nanoparticles. 
 Thus, we tested different rpm in the formation of particles (100 and 500rpm), 
different crosslinking times (30min and 24hrs) and, since our active compound 
(Parvifloron D) is hydrophobic, we had to add an organic solvent to the BSA solution we 
tested different types of organic solvents (hexane, acetone, DMSO and ethanol) and, 
consequently, different ratios of BSA: organic solvent (1:1, 2:1 and 3:1 BSA: Organic 
solvent, respectively). 
 Briefly, 50 mg of BSA was dissolved to 2.0 mL of purified water. Subsequently, 
this solution was added dropwise to absolute ethanol solution under magnetic stirring. 
After the desolvation process, the crosslinking agent was added to induce crosslinking of 
particles. The crosslinking process was carried out under agitation of the suspension over 
a period. The same preparation technique was used in all other groups, although each 
group had different conditions according to the results achieved. 
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 After the optimum rpm was set, four cross-linking groups were added after 
desolvation: A) glutaraldehyde in water was added to induce crosslinking of particles; B) 
placed in the UV chamber under UV light (wavelength 254 nm) for 30 minutes (the 
distance between the light source and the sample was 15 cm); C) glucose was added; D) 
addition of glucose was followed by immediate exposure to the UV source for the same 
time period and same intensity and distance, as mentioned in point C). 160 
 After selecting both the rpm and the crosslinking agent, the latter was tested at 
different time periods and agitation. The last step was the addition of different organic 
solvents to different proportions, to be possible to add the active compound, to verify the 
best solution to achieve the best formulation. 
 
 5.2.2 Toxicity tests on Saccharomyces cerevisiae 
 
 Saccharomyces cerevisiae is referred to as a non-pathogenic unicellular 
eukaryotic organism that has significant genetic characteristics and protein homologies 
like mammals and has been used as a model for numerous toxicological studies. In 
addition it is easy to grow and maintain in laboratory, grows rapidly in a liquid medium, 
tests are quick and affordable and easy to genetically manipulate. 161 
 This yeast is also very useful in toxicity tests involving mechanisms related to 
oxidative stress, since it has the capacity to grow both in the presence and absence of 
oxygen. Through this assay, we intend to study the potential cytotoxicity of BSA 
nanoparticles by testing the effects on the growth of S. cerevisiae when in contact with 
different concentrations of BSA nanoparticle samples. 161,162 
 Saccharomyces cerevisiae (ATCC® 9763 ™) were cultured in yeast extract 
peptone dextrose (YPD) medium containing 1% yeast extract, 0.5% peptone and 2% 
glucose in disposable cuvettes. Subsequently, untreated cultures were used as a negative 
control and serum albumin nanoparticle samples were analyzed at different 
concentrations (3.0 to 5.3 μM). An ultrasonic bath (Bandelin SONOREX Super RK510) 
was used to homogenize the nanoparticle suspensions for 3 minutes. After this process, 
the yeast cultures were added to the samples. The remaining procedure was performed as 
described by Roberto et al. 162 
 Before each absorbance measurement in the spectrophotometer (Thermo 
Scientific Model Evolution 300 BB, UK) at 525 nm, the cultures were vortexed. The 
logarithmic growth curve for each sample, as well as for the control group, was performed 
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by correlating the logarithm of the cell concentration (number of cells / ml) with the 
incubation time. Each group was tested in four replicates (n = 4). For each sample and 
corresponding concentration, growth inhibition was calculated from the linear slope in 
the logarithmic phase of the growth curve of Saccharomyces cerevisiae.162 
 A stability assay of the formulation in the YPD medium, the optimal yeast 
growth medium, was also performed to understand whether it would have any influence 
on the formulation at different concentrations of the yeast. The difference in sample 
preparation was that they were untreated, such as the negative control. 
 
5.3 Results and discussion 
 
 5.3.1 Evaluation of the best nanoparticles producing method 
 
 To select the best method of production of nanoparticles, as well as the ideal 
conditions for a subsequent encapsulation of the active compound (PvD), different 
parameters were evaluated. Throughout the tests the worst hypotheses were excluded 
until the desired conditions were reached, and our goal is to have a particle size between 
100-300 nm and a zeta potential close to zero. 
 The zeta potential characterizes the electric charge of the surface of a particle 
and is a parameter that plays a fundamental role in the various properties of the 
nanoparticles. In addition to the stability of the formulation, the release rate, circulation 
in the bloodstream and absorption in the membranes are also affected by ZP. 163 
 In this case, as our goal is for the formulation to be administered parenterally, 
which will cause the particles to circulate in the bloodstream, the more neutral the charges 
are, i.e. the ZP value closer to zero, greater than biocompatibility from the point of view 
of immunity. 
 Thus, when all parameters described above (particle size, zeta potential and 
crosslinking efficiency (EC (%)) were analyzed, with different rpm (100 and 500rpm), 
we observed that with 500rpm, with the crosslinking group C) (glucose), with 
interconnection time of 30 min and with acetone as an organic solvent, we obtained better 
results. The choice of the interconnection time of 30 min was due to the EC% decrease 
drastically as well as the zeta potential suffering a huge increase over time. Finally, when 
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testing different ratios of BSA: organic solvent, the chosen ratio was 3: 1 BSA: organic 
solvent. 
 
 
 
 
 
 
 
 
Figure 11. Appearance of selected nanoparticles. 
 
 
Figure 12. Results of the study of the formulation of BSA nanoparticles: Different cross-linking 
agent. 
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Figure 13. Results of the study of the formulation of BSA nanoparticles: Different rpm. 
 
 
  
Figure 14. Results of the study of the formulation of BSA nanoparticles: Different cross-linking 
time. 
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Figure 15. Results of the study of the formulation of BSA nanoparticles: Different organic 
solvent.  
 
 
Figure 16. Results of the study of the formulation of BSA nanoparticles: (Different BSA: 
organic solvent proportion). 
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 5.3.2 Toxicity tests on Saccharomyces cerevisiae 
 
 The percentage value of yeast growth inhibition was calculated by determining 
the linear slope in the log phase for each of the samples (Table 4). Exposure of the BSA 
nanoparticle formulation to Saccharomyces cerevisiae cultures demonstrated that at the 
lowest nanoparticle concentration (3,0 μM) there was a growth inhibition of 3.2%, and at 
the highest concentration (5,3 μM) of 15.6%. The negative control was assumed to 
produce zero percentage inhibition of growth (100% yeast growth) in all studies. 
 
 
Table 4. Growth of Saccharomyces cerevisiae cultures exposed to BSA nanoparticles at 
concentrations between 3.0 and 5.3 μM. The growth of Sac. cerevisiae is shown as the natural 
logarithm of cell concentration, expressed as the number of yeast cells / ml. The time interval of 
2-5 hours was considered as logarithmic growth phase (n = 4, mean ± SD). 
 
 
 Additionally, the stability of the formulation in the YPD medium was studied 
to understand if the medium could have any influence on the results of the cytotoxicity, 
and observing Figure 17, it can be verified that the stability of the samples did not 
oscillate considerably. 
 
Concentration 
(μM) 
Exposure 
period (h) 
Ln (Cells/mL) 
Concentration 
(μM) 
Ln (Cells/mL) 
3,0 μM 
2,5 14,66 
3,9 μM 
14,54 
3 14,79 14,72 
3,5 14,96 14,91 
4 15,14 15,05 
4,5 15,23 15,21 
5 15,34 15,26 
Concentration 
(μM) 
Exposure 
period (h) 
Ln (Cells/mL) 
Concentration 
(μM) 
Ln (Cells/mL) 
4,6 μM 
2,5 14,68 
5,3 μM 
14,89 
3 14,86 15,06 
3,5 15,02 15,30 
4 15,18 15,46 
4,5 15,29 15,56 
5 15,47 15,69 
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Figure 17. Study of stability: Absorbances as a function of the time of exposure of the 
formulation to the medium. 
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Chapter 6. Conclusions and future perspectives  
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6. Conclusions and future perspectives  
 
 Pancreatic cancer is one of the oncological pathologies with the highest 
associated mortality rate, the main reason being the stage IV diagnosis, where metastasis 
already exists. 164  
 There are some factors that can be used for prognosis, such as tumor size, lymph 
node involvement and resection margin status. The treatment of this type of cancer is still 
a continuous challenge, since chemoresistance is very associated with this type of cancer 
disease. 165,166 
 Pancreatic cancer results from the interaction between genetic and 
environmental factors, which may be associated with genetic susceptibility and, therefore, 
it is essential that new therapeutic options are developed. 167  
 The therapies so far are mostly based on nonspecific chemotherapy agents. 
However, over the last few years there has been a progression that has led to increased 
interest in the development of molecularly designed, targeted therapies for the treatment 
of pancreatic cancer. Thus, nanotechnology was considered a good strategy to 
encapsulate new molecules that would allow tumor-directed administration of cytotoxic 
drugs. 168,169 
 Clinical trials were performed involving albumin, colloidal gold, iron oxide, 
micelles, liposomes, among others, and demonstrated that nanoparticles can be used in 
conjunction with chemotherapeutic agents and others as they increase their efficacy and 
reduce their toxicity, very present in non-specific chemotherapy. Despite the efficacy 
demonstrated in vivo and in vitro studies in animal models, more research is needed to 
understand the long-term side effects of nanoparticle use, particularly in terms of systemic 
toxicity. 92 
 In the future, if a specific drug with cytotoxic activity can be encapsulated for 
pancreatic tumor cells, in non-toxic nanoparticles that can overcome immunogenicity and 
act only on target cells with high specificity, all the current obstacles associated with the 
treatment can be solved, increasing the overall survival rate of pancreatic cancer patients. 
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